BIOPTSENS AVANZA

The BIOPTSENS AVANZA project is focused on meeting an uncovered and high impact medical need by applying new detection technologies that use a wide panel of protein biomarkers for Alzheimer's disease, combining the use of optoelectronic devices that make rapid detection possible using a small, low-cost device. SPECIFIC GOALS 1 Evaluating the Devices 1.3: Validating and characterising responses from fibre-optic sensor devices with complex samples 2. Confirming Results 2.4: Sensibility and specificity studies on serum samples from seven different neurodegenerative diseases different from Alzheimer's disease (n=600 cases) 3. Analysis and detection of new biomarkers or combinations of biomarkers that help identify Alzheimer's disease 4. Design, evaluation and implementation of improvements geared towards obtaining and developing a potential diagnostic device

At Navarrabiomed

The fluid technologies needed for characterising the union between significant molecules that appear in the sensor have been determined, which is a key step in establishing quality controls for the measurements.
Olfactory structures from people with Alzheimer’s have been characterised to increase the coverage of the biomarkers to detect by the sensors.
In increase in GNPDA2 protein levels in serum from patients with different neurodegenerative diseases has been detected, which is being proposed as a potential biomarker for pathologies that progress with dementia.

At UPNA

Work has been done on improving and optimising the protocol used up to now for both antibody immobilisation to the surface of the fibre and for blocking and detection. The numerous experiments carried out have made it possible to detect the TAU protein in complex cerebrospinal fluid (CSF) dissolutions and serum in concentrations of 0.01 ug/mL.
It should be highlighted that with experiments done up to now it has not been possible to detect TAU concentrations at a clinical level, even though detection in high complexity dissolutions had not been done before, and even though the detection range has been narrowed, there is still room for improvement.
In parallel, work has been done on evaluating improvements geared towards possibly implementing a device based on the technology proposed as a biosensor system with a clinical application.